Summary
Carboplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Breast Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Breast Cancer. ClinicalTrials.gov lists 8 registered trials linking Carboplatin to Breast Cancer: 2 are currently recruiting; 1 has completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT05430347). The largest enrolment is 495 participants (NCT06400472). Registration activity spans 1994 to 2025. The literature layer holds 14 publications for this pair: 5 Cochrane reviews, 3 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2023 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Breast Cancer ranks 1462 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving with modern therapy.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 67.0 (trials 17.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 0 active / not yet recruiting, 1 completed, 5 other |
| Linked publications | 14 (5 Cochrane reviews, 5 clinical trial publications, 3 meta-analyses, 1 systematic review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BRCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01036087 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer 2010 | completed | Phase 2 | 47 |
| NCT04681911 | Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer 2020 | status unknown | Phase 2 | 71 |
| NCT05430347 | Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer 2023 | status unknown | Phase 2 | 80 |
| NCT06400472 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors 2024 | recruiting | Phase 1 | 495 |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors 2017 | terminated | Phase 1 | 107 |
| NCT07525869 | An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy 2025 | recruiting | Not applicable | 40 |
| NCT00002628 | Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer 1994 | status unknown | PHASE1, PHASE2 | 50 |
| NCT01560663 | Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer 2012 | status unknown | Not applicable | 415 |
Published literature
- Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialSeefat RL, Vliek SB, de Jong VMT et al. · The Lancet. Oncology · 2026 · PMID 42372741
- Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancerGong C, Zhao Y, Wang L et al. · ESMO open · 2026 · PMID 41861752
- Clinical trial publication Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 studyMasuda N, Yasojima H, Bando H et al. · Breast cancer research and treatment · 2026 · PMID 41854792
- Clinical trial publication The efficacy of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: a randomized controlled trialKwok ST, Lau LSK, Chan TO et al. · Scientific reports · 2026 · PMID 41851427
- Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudyKuemmel S, Fasching PA, Schmid P et al. · Annals of surgical oncology · 2026 · PMID 41739398
- Cochrane review Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysisMenegat BLRS, Menegat ALRS, Ferreira Piccoli MV et al. · Expert review of anticancer therapy · 2026 · PMID 42030172
- Systematic review A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published EvidenceIsmaili N · International journal of molecular sciences · 2026 · PMID 41752108
- Cochrane review Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysisDu Y, Huang L · Discover oncology · 2025 · PMID 40817946
- Cochrane review Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysisLiu S, Li X, Wu C et al. · International journal of surgery (London, England) · 2025 · PMID 40422076
- Meta-analysis Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysisWu J, Yan X, Fang J et al. · Medicine · 2025 · PMID 41054152
- Meta-analysis Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysisLiutti VT, do Vale DL, de Souza BL et al. · Breast cancer research and treatment · 2025 · PMID 40512324
- Meta-analysis The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysisLiu S, Yu M, Mou E et al. · Scientific reports · 2025 · PMID 39753653
- Cochrane review Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysisPetrelli F, Ghidini A, Rea C et al. · Current problems in cancer · 2024 · PMID 38608530
- Cochrane review Platinum-based chemotherapy for early triple-negative breast cancerMason SR, Willson ML, Egger SJ et al. · The Cochrane database of systematic reviews · 2023 · PMID 37681577
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Carboplatin approved for Breast Cancer?
Carboplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Breast Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Breast Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Carboplatin in clinical trials for Breast Cancer?
ClinicalTrials.gov lists 8 registered trials linking Carboplatin to Breast Cancer: 2 are currently recruiting; 1 has completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT05430347). The largest enrolment is 495 participants (NCT06400472). Registration activity spans 1994 to 2025.
What does the evidence show for Carboplatin in Breast Cancer?
Carboplatin has both completed registered trials and synthesis-level publications linked to Breast Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.